Payment overview · 2025
General Payments
$2,889.23
119 reported records · 15 companies
Healthcare provider profile · identity verified
Leo Yankilevich, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1255355632
Verified facts
What the public records show
CMS Open Payments records show Leo Yankilevich, MD received $2,889.23 in general payments during 2025 across 119 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Caplyta, Creon, Eliquis, Farxiga, Linzess, Lybalvi, Otezla, Qulipta, Trelegy Ellipta, Ubrelvy, Xifaxan, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 300 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 255 claims for Zenpep by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lybalvi by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Auvelity by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 300 claims for Linzess by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Caplyta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $499.97 | 17.3% | 21 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $451.81 | 15.6% | 18 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $373.90 | 12.9% | 20 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $365.16 | 12.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $257.89 | 8.9% | 15 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $185.53 | 6.4% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $173.32 | 6.0% | 8 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $151.92 | 5.3% | 7 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $136.96 | 4.7% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $120.08 | 4.2% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $55.00 | 1.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.03 | 1.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.03 | 0.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.83 | 0.8% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $20.80 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,889.23 | 119 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $451.81 | 18 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $373.90 | 20 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $365.16 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $351.11 | 14 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $185.53 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $173.32 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $173.32 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $151.92 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $148.86 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $143.55 | 9 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $136.96 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $122.05 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $120.08 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $114.34 | 6 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $65.11 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $55.00 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.03 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 58 | exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 93 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 129 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 163 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 300 | exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 22 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 52 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 255 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
93 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
300 | 41 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
87 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
255 | 38 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
22 | 12 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
163 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
300 | 41 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
58 | 18 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
198 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
129 | 23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
52 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 580 | 84 |
| Losartan Potassium | Losartan Potassium | 414 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 357 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 314 | 60 |
| Linzess | Linaclotide | 300 | 41 |
| Metformin Hcl | Metformin Hcl | 297 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 285 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 257 | 39 |
| Zenpep | Lipase/Protease/Amylase | 255 | 38 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 240 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 226 | 33 |
| Vascepa | Icosapent Ethyl | 224 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 215 | 35 |
| Entresto | Sacubitril/Valsartan | 198 | 21 |
| Gabapentin | Gabapentin | 185 | 24 |
| Furosemide | Furosemide | 184 | 34 |
| Omeprazole | Omeprazole | 178 | 40 |
| Azithromycin | Azithromycin | 171 | 99 |
| Myrbetriq | Mirabegron | 170 | 20 |
| Carvedilol | Carvedilol | 166 | 22 |
| Simvastatin | Simvastatin | 166 | 23 |
| Farxiga | Dapagliflozin Propanediol | 163 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 133 | 26 |
| Meloxicam | Meloxicam | 131 | 25 |
| Eliquis | Apixaban | 129 | 23 |
| Famotidine | Famotidine | 122 | 18 |
| Clonidine Hcl | Clonidine Hcl | 115 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 18 |
| Ezetimibe | Ezetimibe | 111 | 13 |
| Meclizine Hcl | Meclizine Hcl | 107 | 23 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 105 | 13 |
| Jardiance | Empagliflozin | 101 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 17 |
| Ozempic | Semaglutide | 99 | 13 |
| Enalapril Maleate | Enalapril Maleate | 97 | 13 |
| Memantine Hcl Er | Memantine Hcl | 97 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 97 | 21 |
| Dexilant | Dexlansoprazole | 96 | suppressed |
| Celecoxib | Celecoxib | 95 | 32 |
| Creon | Lipase/Protease/Amylase | 93 | 27 |
| Ibuprofen | Ibuprofen | 92 | 37 |
| Lisinopril | Lisinopril | 92 | 15 |
| Glipizide | Glipizide | 90 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 87 | 20 |
| Synthroid | Levothyroxine Sodium | 87 | suppressed |
| Potassium Chloride | Potassium Chloride | 81 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 78 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 78 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 76 | suppressed |
| Otezla | Apremilast | 74 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 74 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 69 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 33 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 69 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 66 | 26 |
| Icosapent Ethyl | Icosapent Ethyl | 66 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 64 | suppressed |
| Gemtesa | Vibegron | 64 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 64 | 21 |
| Dicyclomine Hcl | Dicyclomine Hcl | 61 | suppressed |
| Glimepiride | Glimepiride | 60 | suppressed |
| Caplyta | Lumateperone Tosylate | 58 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 46 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 57 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 57 | 14 |
| Restasis | Cyclosporine | 54 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 53 | suppressed |
| Cyclosporine | Cyclosporine | 53 | suppressed |
| Ibsrela | Tenapanor Hcl | 52 | 12 |
| Xifaxan | Rifaximin | 52 | 31 |
| Ammonium Lactate | Ammonium Lactate | 50 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | 11 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 48 | 18 |
| Glipizide Er | Glipizide | 48 | suppressed |
| Nifedipine Er | Nifedipine | 48 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 48 | suppressed |
| Spironolactone | Spironolactone | 45 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | 11 |
| Silver Sulfadiazine | Silver Sulfadiazine | 43 | 11 |
| Labetalol Hcl | Labetalol Hcl | 42 | suppressed |
| Nitroglycerin | Nitroglycerin | 41 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Ubrelvy | Ubrogepant | 39 | suppressed |
| Jublia | Efinaconazole | 37 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | suppressed |
| Tradjenta | Linagliptin | 37 | suppressed |
| Lactulose | Lactulose | 35 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 35 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 33 | suppressed |
| Febuxostat | Febuxostat | 33 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 33 | suppressed |
| Prednisone | Prednisone | 33 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 32 | suppressed |
| Ketoconazole | Ketoconazole | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 31 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 13 |
| Clonazepam | Clonazepam | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Xiidra | Lifitegrast | 28 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 27 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Ibu | Ibuprofen | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | suppressed |
| Trulance | Plecanatide | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Baclofen | Baclofen | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 18 |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Crestor | Rosuvastatin Calcium | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Qulipta | Atogepant | 23 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 22 | 12 |
| Advair Diskus | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Metronidazole | Metronidazole | 21 | suppressed |
| Opzelura | Ruxolitinib Phosphate | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Roflumilast | Roflumilast | 20 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Latuda | Lurasidone Hcl | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Enbrel Sureclick | Etanercept | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Proctozone-Hc | Hydrocortisone | 14 | suppressed |
| Wellbutrin Xl | Bupropion Hcl | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Misoprostol | Misoprostol | 13 | suppressed |
| Prevacid | Lansoprazole | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 11 | suppressed |
| Licart | Diclofenac Epolamine | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,889.23 · 119 records | AstraZeneca Pharmaceuticals LP | Auvelity, BREZTRI, CAPLYTA, CREON, ELIQUIS, FARXIGA, LEQVIO, LINZESS, LYBALVI, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, TREMFYA, UBRELVY, XIFAXAN, YUPELRI, ZENPEP | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error